2. NF-κB Others Autophagy
  3. NF-κB Fluorescent Dye Drug Derivative Autophagy
  4. Anticancer agent 327

Anticancer agent 327, a fluorescent Andrographolide (HY-N0191) derivative, is an NF-κB p50 inhibitor. Anticancer agent 327 covalently binds to the p50 subunit of NF-κB. Anticancer agent 327 reduces levels of multiple oncogenic p53 proteins via the autophagy/lysosome pathway. Anticancer agent 327 can be used for the research of pancreatic ductal adenocarcinoma (Ex/Em = 488/515 nm)[1].

For research use only. We do not sell to patients.

Anticancer agent 327

Anticancer agent 327 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 327 Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 327, a fluorescent Andrographolide (HY-N0191) derivative, is an NF-κB p50 inhibitor. Anticancer agent 327 covalently binds to the p50 subunit of NF-κB. Anticancer agent 327 reduces levels of multiple oncogenic p53 proteins via the autophagy/lysosome pathway. Anticancer agent 327 can be used for the research of pancreatic ductal adenocarcinoma (Ex/Em = 488/515 nm)[1].

In Vitro

Anticancer agent 327 (Compound 4) (1-30 μM; 48 h) potently reduces viability of PANC-1 and MIA PaCa-2 PDAC cells with IC50 values of 9.94 μM and 25.30 μM, respectively[1].
Anticancer agent 327 (1-30 μM; 2-24 h) significantly reduces levels of oncogenic p53R273H in PANC-1 cells and p53R248W in MIA PaCa-2 cells in a concentration- and time-dependent manner[1].
Anticancer agent 327 (10 μM; 24 h) reduces oncogenic p53R273H protein levels in PANC-1 cells primarily through the autophagy pathway[1].
Anticancer agent 327 (1-30 μM; 24 h) potently inhibits long-term proliferation of PANC-1, MIA PaCa-2, and KPC PDAC cells, with the greatest activity against PANC-1 cells[1].
Anticancer agent 327 (1-30 μM; 10-24 h) suppresses migration of PANC-1, MIA PaCa-2, and KPC PDAC cells in a concentration-dependent manner, with the strongest activity against KPC cells[1].
Anticancer agent 327 (5-10 μM; 12 h) downregulates transcription of multiple cancer-related genes downstream of oncogenic TP53R273H, without altering TP53 mRNA levels[1].
Anticancer agent 327 (6 μM; 5 min-48 h) is rapidly taken up by PANC-1 cells, with detectable fluorescent signals within 5 min, and remains stably retained for at least 48 h[1].
Anticancer agent 327 (1-10 μM; 1 h at 25 °C) covalently binds to the NF-κB p50 subunit in vitro in a concentration-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 327 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: human pancreatic ductal adenocarcinoma (PDAC) cell lines PANC-1 (p53R273H), MIA PaCa-2 (p53R248W)
Concentration: 1 μM; 3 μM; 10 μM; 30 μM
Incubation Time: 48 h
Result: Exhibited concentration-dependent cytotoxicity in both cell lines.
Had an IC50 of 9.94 μM in PANC-1 cells, with significant viability reduction at all tested concentrations.
Had an IC50 of 25.30 μM in MIA PaCa-2 cells, with significant viability reduction at 30 μM.

Western Blot Analysis[1]

Cell Line: human PDAC PANC-1 (p53R273H) cells
Concentration: 1 μM; 3 μM; 5 μM; 10 μM; 20 μM
Incubation Time: 2 h; 6 h; 12 h; 24 h
Result: Significantly upregulated the autophagy marker LC3-II.
Caused time-dependent and concentration-dependent reduction of p53R273H.

Western Blot Analysis[1]

Cell Line: MIA PaCa-2 (p53R248W)
Concentration: 3 μM; 5 μM; 10 μM; 20 μM; 30 μM
Incubation Time: 2 h; 6 h; 12 h; 24 h
Result: Caused time-dependent and concentration-dependent reduction of p53R248W levels.

Cell Proliferation Assay[1]

Cell Line: human PDAC cell lines PANC-1 (p53R273H), MIA PaCa-2 (p53R248W), mouse PDAC cell line KPC (p53R172H)
Concentration: 1 μM; 3 μM; 5 μM; 10 μM; 30 μM
Incubation Time: 24 h
Result: Significantly suppressed colony formation in all three cell lines in a concentration-dependent manner.
Showed the strongest effect on colony formation in PANC-1 cells.

Cell Migration Assay [1]

Cell Line: human PDAC cell lines PANC-1 (p53R273H), MIA PaCa-2 (p53R248W), mouse PDAC cell line KPC (p53R172H)
Concentration: 1 μM; 3 μM; 10 μM; 30 μM
Incubation Time: 10 h; 12 h; 24 h
Result: Suppressed migration of PANC-1 and KPC cells in a concentration-dependent manner, with no apparent cytotoxicity during the incubation period.
Reduced migration of MIA PaCa-2 cells only at 30 μM, with cytotoxicity observed at this concentration.
Caused greater suppression of migration in KPC cells than PANC-1 cells.

Real Time qPCR[1]

Cell Line: human PDAC PANC-1 (p53R273H) cells
Concentration: 5 μM; 10 μM
Incubation Time: 12 h
Result: Significantly reduced mRNA levels of CCNA2, PCNA, CXCL1, CXCL2, CXCL8, TIGAR, and MYC in a concentration-dependent manner.
Did not affect TP53 mRNA levels, indicating post-transcriptional regulation of p53R273H.
Suppressed MYC expression, unlike andrographolide.
In Vivo

Anticancer agent 327 (Compound 4) (10-20 mg/kg; i.p.; every 2 days; 4 total doses) exhibits no observable in vivo toxicity in 4-week-old immunocompetent C57BL/6 mice at the tested dosing regimen[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male; 4 weeks old)[1]
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; every 2 days; 4 total doses
Result: Did not affect the body weights of treated mice.
Showed no evident liver or kidney toxicity, as indicated by serum biochemical parameters and histological analyses of liver and kidney tissues.
Molecular Weight

568.62

Formula

C29H36N4O8
SMILES

CN(CC1OC[C@]([C@](CCC([C@H]2C/C=C3C(OC[C@H]/3O)=O)=C)([H])[C@@]2(C)CC4)(C)[C@@H]4O1)C5=CC=C([N+]([O-])=O)C6=NON=C56
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 327 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 327Anticancer agent327Anticancer agent-327NF-κBFluorescent DyeDrug DerivativeAutophagyNuclear factor-κBNuclear factor-kappaBDrug derivativeNF-κB p50 subunitp53R273Hpancreatic ductal adenocarcinoma cellsMIA PaCa-2 cellsautophagy/lysosome pathwayKPC PDAC cellsp53R248WC57BL/6 micePANC-1 cellsoncogenic p53 proteinsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 327
Cat. No.:
HY-183786
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.